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Abstract
Background: Lung cancer (LC) is the leading cause of cancer-related deaths. Oxidative DNA
damage may contribute to the cancer risk. The antioxidant paraoxonase (PON1) is an endogenous
free radical scavenger in the human body. The aim of this study was to determine serum PON1 and
arylesterase (ARE) activities in patients with newly diagnosed LC.
Methods:  This case control study involved a total of 39 patients with newly diagnosed LC
(untreated) and same number of age- and sex-matched healthy individuals. Serum PON1 and ARE
activities in addition to lipid parameters were measured in both groups.
Results: Serum PON1 and ARE activities were found to be lower in patients with LC compared
to the controls (p = 0.001 and p = 0.018, respectively). The ratio of PON1/high density lipoprotein
(HDL) was significantly lower in the LC group compared to the control one (p = 0.009). There
were positive correlations between the serum levels of HDL and PON1 in both the control (r =
0.415, p = 0.009) and the LC groups (r = 0.496, p = 0.001), respectively. PON1 enzyme activity was
calculated as three different phenotypes in both groups. In regard to lipid parameters, total
cholesterol levels were significantly lower (p = 0.014) in the LC group whereas the other lipid
parameters such as HDL, LDL, and triglyceride levels were not significantly different among groups.
Conclusion: Serum PON1 activity is significantly low in the LC group compared with the healthy
controls. Metastasis status and cigarette smoking do not affect serum PON1 activity in the LC
patients.
Background
Lung cancer (LC) is among the most common malignan-
cies in the Western World and is the leading cause of can-
cer deaths in both men and women. It is one of the few
tumors with a known carcinogen, namely tobacco, con-
tributing to its etiology. Since cigarette smoking was noted
in 80% to 90% of patients with LC, the leading cause of
LC is accepted to be smoking [1,2].
An elevated oxidative status has been found in many types
of cancer cells, and the introduction of chemical and enzy-
matic antioxidants can inhibit tumour cell proliferation
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[3]. High doses and/or inadequate removal of reactive
oxygen species (ROS) result in oxidative stress, which may
cause severe metabolic malfunctions and damage to bio-
logical molecules including DNA [4]. It is well known that
oxidative stress induced by environmental carcinogen
exposure may affect cellular functions in various patho-
logical conditions, including cancer [5,6].
Human serum paraoxonase (PON1) and arylesterase
(ARE) are esterase enzymes that have lipophilic antioxi-
dant characteristics. Serum PON1 binds to high density
lipoprotein (HDL) and contributes to the elimination of
organophosphorus compounds, such as paraoxon, and
carcinogenic lipid soluble radicals from lipid peroxida-
tion. PON1 is one of the endogenous free-radical scaveng-
ing systems in the human body [7-9]. Serum PON1
together with ARE have been demonstrated to function as
a single enzyme [10]. PON1 activity varies widely among
individuals, partly related to polymorphisms. The PON1
gene has two common coding region polymorphisms
[11]. A genetic polymorphism of PON1 activity deter-
mines high versus low paraoxon hydrolysis in human
populations [12]. PON1 also has ARE activity, which does
not exhibit activity polymorphism and can therefore
serves as an estimate of enzyme protein [13]. Human
serum PON1 shows neither age-related change in activity
nor gender differences [14]. However, diet, cigarette
smoking, acute phase proteins, and pregnancy affect
serum PON1 levels and activities [15-17]. Reduced PON1
activities have been reported in several groups of patients
with diabetes mellitus, hypercholesterolemia and cardio-
vascular disease who are under increased oxidative stress
[18,19]. There are relatively few studies on in PON1 activ-
ity in cancer. Serum levels of PON1 were lower in patients
with pancreatic or gastric cancer than in healthy controls
in two case-control studies. Despite these initial findings,
the interaction of serum PON1 levels with cancer is not
completely known [15,20,21]. It has been emphasized
that PON1 polymorphisms might contribute to the
increased risk of cancer in associated with pollutants and
other environmental chemicals [22].
The aim of this study was to investigate the activity of
serum PON1 in patients with LC, compared to that of
healthy controls, and to investigate possible alterations in
relation to the stage and type of LC.
Methods
The study population
This case-control study was conducted at the Department
of Internal Medicine of the Firat (Euphrates) University
Hospital setting in Elazig, Turkey, between December
2004 and June 2005. A total of 44 patients were admitted
during the period. However two of them were excluded
from the study due to history of taking antilipidemic drug,
three of them were also not eligible for the study due to
history of taking chemotherapy. The remaining 39
patients with previously untreated, histopathologically
verified newly diagnosed as of LC and 39 age- and sex-
matched healthy volunteers were enrolled into this study.
Informed consents were obtained from patients prior to
the study. The study protocol and the procedures were
approved by Firat University Local Ethical Committee,
and all subjects were recruited upon obtaining informed
consent. Subjects' history and physical examinations were
documented. The diagnosis of LC was based on his-
topathologic findings. Nine out of 39 patients were small
cell LC, 16 were squamous cell LC, 14 were adenocarci-
noma type. Cases either study group or control, who had
pathologies that could cause secondary lipid disorders,
cardiovascular diseases, diabetes mellitus, renal failure,
chronic infection and inflammation, alcohol abuse, and
those who used antilipidemic and antioxidant drugs were
excluded from the study. Additionally, LC patients with
previously performed chemotherapy, radiotherapy and
surgery were also excluded from the study.
Serum samples
Blood samples were collected in tube (BD diagnostics-pre-
analytic systems, UK) at 0800–0900 A.M. after 8–12
hours of fasting. Professional staff performed venipunc-
ture, using vacutainers to obtain 10 mL of whole blood.
Since calcium EDTA inhibits PON1 activity, calcium
EDTA containing tubes were not used for collecting serum
samples. The samples were centrifuged at 3500 rpm for 5
min. and serum samples were stored at -20°C until
assayed.
Serum levels of total cholesterol, triglyceride, HDL-choles-
terol and low density lipoprotein (LDL)-cholesterol were
determined by means of an Olympus AU 600 autoana-
lyzer (Olympus Optical Co., Japan) using commercially
available assay kits. Serum total cholesterol, triglyceride,
HDL-cholesterol and LDL-cholesterol levels were meas-
ured at the same day that the blood was collected.
Assay of serum paraoxonase and arylesterase activities
Paraoxonase activity was determined spectrophotometri-
cally using paraoxon (O, O-diethyl-o-p-nitro-phenyl-
phosphate; Sigma Chemical Co) as the substrate and
measured by increases in the absorbance at 412 nm due to
the formation of 4-nitrophenol as already described [23].
Briefly, the activity was measured at 25°C by adding 50 μl
of serum to 1 ml Tris-HCl buffer (100 nM at pH 8.0) con-
taining 2 mM CaCl2 and 5.5 mM of paraoxon. The rate of
generation of 4-nitrophenol was determined at 412 nm
with a spectrophotometer (Techcomp 8500 II UV/VIS,
China). PON1 activity is expressed in U/l serum. One unit
of PON1 activity was defined as 1 nmol of 4-nitrophenol
formed per minute under the above assay conditions.BMC Cancer 2007, 7:48 http://www.biomedcentral.com/1471-2407/7/48
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Arylesterase activity was also measured spectrophotomet-
rically using phenylacetate (Sigma Co, London, UK) as
the substrate. The phenol formed after the addition of a
40-fold diluted serum sample was measured spectropho-
tometrically at 217 nm following an established proce-
dure [24]. The activity of ARE was expressed in kU/l
serum. One unit was defined as the enzyme quantity that
disintegrates 1 nmol phenylacetate per minute.
The phenotypic distribution of paraoxonase
The phenotypic distribution of PON1 activity was deter-
mined by the dual substrate method. Three phenotypes
were determined in the study groups by taking the ratio of
PON1 activity to arylesterase activity. The ratio of hydrol-
ysis of paraoxon in the presence of 1 M NaCl (salt-stimu-
lated PON1) to the hydrolysis of phenylacetate was used
to classify individuals to one of the three possible pheno-
types; AA (homozygote low activity), AB (heterozygote
activity) and BB (homozygote high activity) [25]. Pheno-
type of PON1 activity according to the PON1/ARE rate
was also performed individually for each group and three
different phenotypes were determined for each group. The
PON1/ARE rates of LC patients were considered as: 0.56–
1.55 AA, 1.56–3.10 AB and 3.11–4.66 BB phenotypes,
respectively. The PON1/ARE rates for the control group
were considered as: 0.94–1.14 AA, 1.15–2.28 as AB, 2.29–
3.50 as BB phenotypes, respectively.
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware package, version 10.0 for Windows. Clinical labora-
tory data were expressed as mean ± standard deviation.
Mean values were compared between patients with LC
and healthy individuals by Student's t test. Mann Whit-
ney-U  test was used to assess the mean differences
between smoker LC patients and smoker control, and
between metastatic and nonmetastatic LC patients. The
Pearson's correlation analysis was used to assess the rela-
tionship between PON1 activity and HDL cholesterol lev-
els. The analysis of variance (ANOVA) test was used to
compare biochemical parameters among small cell carci-
noma, squamous cell carcinoma and adenocarcinoma.
Stepwise multivariate linear regression analyses (with
95% confidence intervals) were performed by considering
the PON1 activity as the dependent variable. The possible
associations between serum PON1 and independent vari-
ables (total cholesterol, HDL cholesterol, triglyceride lev-
els, stage of disease and metastasis status) were followed.
A value of p < 0.05 was considered as statistically signifi-
cant.
Results
The demographic features and biochemical parameters of
LC patients and controls are presented in the Table 1. Out
of the 39 patients with LC, 38 (97%) of the patients were
males and 1 (3%) was female. The mean age was 64.4 ±
8.9 years (range, 50–85 years). Thirty had non-small cell
LC (16 squamous cell LC, 14 adenocarcinoma type), nine
had small cell LC. Patients were staged according to the
American Joint Committee on Cancer (AJCC) staging sys-
tem. Nine patients had stage II disease, 10 had stage III
and the remaining 20 had stage IV disease. The control
group was consisted of 39 healthy individuals, 38 males
and 1 female with mean age of 64.05 ± 8.6 years (range,
50–85 years). The mean age and sex distribution were
similar in both groups. In addition, there was no differ-
ence in race among groups. The mean serum PON1 activ-
ities were 395.8 ± 116.6 U/mL and 252.7 ± 104.4 U/mL in
the control group and in the patients with LC, respec-
tively. When compared to healthy controls, serum ARE
activity were lower in patients with LC which was statisti-
cally significant (Table 1). Serum HDL cholesterol, LDL
cholesterol and triglyceride levels were not significantly
different among groups. Although not statistically signifi-
cant, the HDL cholesterol levels, serum HDL level and
PON1 activity were lower in LC patients. The PON1 activ-
ity was standardized with HDL concentrations (PON1/
HDL ratio). It was found that the standardized PON1
enzyme activity was significantly lower in the LC patients
(8.1 ± 2.9) as compared with controls (9.8 ± 2.9; p =
0.009). The serum total cholesterol level in patients with
LC was significantly lower compared with healthy sub-
jects (p = 0.014) (Table 1).
There was no statistical difference between the biochemi-
cal parameters among small cell carcinoma, squamous
cell carcinoma and adenocarcinoma in any stage (Table
2).
It was found in the smoker LC patients that serum PON1
and ARE activities was significantly lower compared with
smoker controls. Serum PON1 activity in the smoker LC
patients was markedly lower (p < 0.001) than that of the
smoker control subjects. Similarly, serum ARE activity in
the smoker LC patients was lower. Serum ARE activities
were 175.3 ± 48.7 U/L and 143.6 ± 57.3 U/L; in the
smoker control subjects and in the smoker LC patients,
respectively (p = 0.025). In the smoker control subjects,
serum HDL cholesterol levels were significantly higher (p
< 0.001) than that of the smoker LC patients (Table 3).
As shown in the Table 4, no statistically significant differ-
ences were observed in serum PON1 and ARE activities
between metastatic and nonmetastatic LC patients. Serum
PON1 activity was 259.5 ± 94.9 U/mL in the patients with
metastatic LC whereas it was 245.6 ± 115.7 U/mL in the
patients with nonmetastatic LC (p = 0.70). The mean
serum ARE activities were 153.9 ± 62.9 U/L and 153.9 ±BMC Cancer 2007, 7:48 http://www.biomedcentral.com/1471-2407/7/48
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62.9 U/L in the metastatic LC patients and in the nonmet-
astatic LC patients (p = 0.09).
We determined the phenotype distribution of our study
groups by taking the ratio of PON1 activity to arylesterase
activity. The distribution of paraoxonase phenotypes in
LC patients and controls was as follows: AA (homozygote
low activity), 36% and 3%, AB (heterozygote activity)
51% and 35%, BB (homozygote high activity) 13% and
62%, respectively. Serum PON1 levels in the individuals
with AA, AB, and BB phenotypes in the LC group were
lower than the same phenotype individuals in the control
group.
There was established positive correlation between serum
PON1 activity and serum level of HDL cholesterol (r =
0.496, p = 0.001) in patients with LC. Similarly, serum
PON1 activity also correlated positively with serum HDL
cholesterol level (r = 0.415, p = 0.009) in the control
group (Figures 1 and 2).
Multiple linear regression analysis of the variables was
also performed by considering the PON1 as the depend-
ent variable. It was determined that total cholesterol, HDL
cholesterol, triglyceride levels, stage of disease and pres-
ence or absence of metastasis was not the determining fac-
tor for the PON1 activity (Table 5).
Discussion
Reactive oxygen species molecules are highly reactive and
can attack almost every cell component, causing further
damage to the surrounding tissues. An elevated oxidative
stress and free oxygen radicals have been associated with
the increased risks of various cancers. End products of
lipid peroxidation and scavenging system elements have
been thought to play a role in oncogenesis [26-28]. Kay-
nar et al. studied the activities of antioxidant enzymes and
demonstrated that erythrocyte malondialdehyde, nitric
oxide, total glutathione levels and erythrocyte superoxide
dismutase, catalase and xanthine oxidase activities were
significantly higher in patients with LC than in controls.
This study indicates significant changes in antioxidant
defense system in LC patients, which may lead to
enhanced action of oxygen radicals, resulting in lipid per-
oxidation [29]. One of the lipid peroxidation end prod-
ucts, malondialdehyde level in patients with LC has been
found significantly higher than those in controls [30].
Carcinogenic lipid soluble radicals are formed as a result
of lipid peroxidation and PON1 binds to these radicals.
PON1 has been shown to metabolize lipid-soluble radi-
Table 2: Serum paraoxonase activity and biochemical parameters in small cell lung cancer adenocarcinoma and epidermoid 
carcinoma patient groups
SCLC (n = 9) AC (n = 14) EC (n = 16) P value
Total cholesterol (mg/dl) 158.9 ± 30.7 170.9 ± 45.6 163.5 ± 63.1 0.849
LDL cholesterol (mg/dl) 115.4 ± 26.3 118.2 ± 41.1 114.4 ± 52.1 0.971
HDL cholesterol (mg/dl) 30.3 ± 4.3 34.2 ± 9.9 38 ± 31.3 0.680
VLDL cholesterol (mg/dl) 33.9 ± 15 27.8 ± 8.7 28.1 ± 11.6 0.504
Triglyceride (mg/dl) 158.8 ± 68.8 131.4 ± 37.1 140.1 ± 58.2 0.395
PON1 (U/mL) 233.9 ± 70.5 273.1 ± 118.1 245.4 ± 110.5 0.649
ARE (U/L) 163 ± 69.5 115.7 ± 44.2 142 ± 57.2 0.144
PON1/ARE 1.7 ± 0.9 2.5 ± 0.9 1.8 ± 0.7 0.062
Values are mean ± S.D. SCLC:Small Cell carcinoma, AC: Adenocarcinoma, EC:Epidermoid carcinoma, PON1: paraoxonase, ARE: arylesterase
Table 1: Demographic features, paraoxonase activity and biochemical parameters in controls and lung cancer patient groups
Control group (n = 39) Patient group (n = 39) P value
Age (year) 64.0 ± 8.6 64.4 ± 8.9 0.861
Cigarette smoking (%) 64.1 89.7 0.014
Total cholesterol (mg/dl) 193.2 ± 48.5 165.1 ± 50 0.014
LDL cholesterol (mg/dl) 128.8 ± 35.3 116 ± 42.4 0.152
HDL cholesterol (mg/dl) 41.7 ± 10.9 34.9 ± 20.8 0.074
VLDL cholesterol (mg/dl) 32 ± 16.3 29.3 ± 11.5 0.393
Triglyceride (mg/dl) 160.8 ± 81.7 141.3 ± 53.9 0.219
PON1 (U/mL) 395.8 ± 116.6 252.7 ± 104.4 0.001
ARE (U/L) 167.7 ± 45 137.4 ± 57.6 0.018
PON1/ARE 2.4 ± 0.6 2.0 ± 0.9 0.008
PON/HDL 9.8 ± 2.9 8.1 ± 2.9 0.009
Values are mean ± S.D. PON1: paraoxonase, ARE: arylesteraseBMC Cancer 2007, 7:48 http://www.biomedcentral.com/1471-2407/7/48
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cals [15,31]. Serum PON1 activity was suggested to be
inversely associated with oxidative stress in serum and
macrophages and that PON1 deficiency results in
increased oxidative stress [32]. In our study, serum PON1
activity was found to be significantly lower in patients
with LC compared to healthy individuals. Some studies
have established a positive correlation between PON1
mutations and the risk of cancer. However, the data are
conflicting and other studies revealed no evidence for an
association with malignancy. A case-control study which
contains 177 patients by Lee et al. [33] showed that the
risk of developing LC were significantly increased in indi-
viduals carrying the PON1 gene Q/Q genotype. It was also
stated that, this correlation could not be established with
the R/R or Q/R genotypes of the PON1 gene in this study.
To the best of our knowledge, our study is the first to state
the association between PON1 and LC in the English Lit-
erature. Similar to the aforementioned study, we observed
that in LC patients, PON1 activity was reduced and not
influenced by the cigarette smoking and metastasis status
of subjects. In our study, we have not performed any gen-
otypical analysis due to technical limitations. Kerridge et
al. [34] found that PON1 BB gene (Arg 192 isoform) pol-
ymorphism was associated with risk of non-Hodgkin's
lymphoma. A cohort study found no association between
PON1 polymorphism and prostate cancer [35], whereas
another case-control study demonstrated that men with
PON192/QQ had a significantly increased risk for pros-
tate cancer compared with PON192/RR genotype [36]. In
a prospective study of Stevens et al. it was reported that
L55 M PON1 genotype may have increased risk factor for
breast cancer in postmenopausal women, whereas the
Q192R single nucleotide polymorphism was not associ-
ated with breast cancer incidence [37]. The study of Kafa-
dar et al. showed that serum PON1 activity is significantly
lower in patients with high grade glioma and meningi-
oma compared to control subjects [38]. Other investiga-
tors have not reported any significant differences in PON1
genotype distributions in patients with colorectal cancer
comparison to healthy individuals [39].
In our study, we found decreased activities of PON1 and
ARE enzymes in patients with LC comparison to the group
of healthy individuals. To assess whether the observed
reduction of PON1 activity was due to the reduced HDL
level, we standardized the enzyme activity for HDL con-
centration (PON1/HDL) and found that the standardized
enzyme activities were lower in patient group compared
to the controls (p = 0.009). Positive correlation was deter-
mined between serum PON1 activity and HDL choles-
terol. These data indicate that PON1 activity changes are
not entirely dependent on HDL concentration in this
study group.
Lipid peroxidation, as a well-known index of ROS activity,
is an oxidative stress associated with membrane lipid
destruction. Previous studies have reported increased
lipid peroxidation in cancer tissues, in serum and in eryth-
rocytes of patients with LC [30,40,41]. The serum PON1
activity is highly variable and its regulation is complex.
Moreover the mechanism of the reduction of serum
PON1 activity in LC patients is not clearly understood.
This reduction could be related to increased lipid peroxi-
dation, since oxidized lipids are reported to inhibit PON1
activity [42]. In addition, the activity of PON1 has been
reported to be significantly reduced in some conditions
Table 4: Paraoxonase activity and biochemical parameters in metastatic and non-metastatic lung cancer patients
Nonmetastatic LC patients (n=19) Metastatic LC patients (n=20) P value
Total cholesterol (mg/dl) 169.7 ± 57.6 160.7 ± 42.7 0.66
LDL cholesterol (mg/dl) 115.3 ± 45.8 116.6 ± 40.1 0.94
HDL cholesterol (mg/dl) 38.8 ± 28.5 31.1 ± 8.1 0.62
Triglyceride (mg/dl) 149.9 ± 55.7 133.2 ± 52.4 0.41
PON1 (U/mL) 245.6 ± 115.7 259.5 ± 94.9 0.70
ARE (U/L) 120 ± 47 153.9 ± 62.9 0.09
Values are mean ± S.D. LC: Lung cancer, PON1: paraoxonase, ARE: arylesterase
Table 3: Paraoxonase and arylesteraz activies in smoker controls and smoker lung cancer patients
Smoker controls (n = 25) Smoker LC patients (n = 35) P value
PON1 (U/mL) 412.9 ± 121.9 263.8 ± 104.5 0.001
ARE (U/L) 175.3 ± 48.7 143.6 ± 57.3 0.025
HDL cholesterol (mg/dl) 42.6 ± 11.1 32.6 ± 8.6 0.001
PON1/HDL cholesterol 10 ± 3.2 8.3 ± 3.3 0.047
Values are mean ± S.D. LC: Lung cancer, PON1: paraoxonase, ARE: arylesteraseBMC Cancer 2007, 7:48 http://www.biomedcentral.com/1471-2407/7/48
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accompanying oxidative stress and inflammatory condi-
tions, including rheumatoid arthritis, ulcerative colitis
and Behcet's disease [43,44]. Similarly, reduced serum
PON1 activity in patients with LC could be a result of
increased activity of ROS in LC. Cigarette smoking has
also been shown to decrease serum PON1 levels and activ-
ity [45]. In our study, when smoking status of each group
were considered, we found that in the smoker LC patients,
serum PON1 and ARE activities was significantly lower
compared with smoker healthy controls (p < 0.001).
Standardized enzyme activities of PON1/HDL were also
lower in smoker patient group compared to smoker con-
trols (p = 0.047). These results suggest the reduction of
PON1 activity in patients with LC was independent from
cigarette smoking.
Conclusion
This study showed that serum PON1 and ARE activities
were significantly lower in LC patients compared to
healthy subjects. These observations suggested the
hypothesis that defects in the antioxidant system capacity
and altered PON1 activity may be involved in the patho-
genesis of LC. But, these preliminary results are needed to
be verified by large numbered prospective studies to
reveal the possible association between PON1 and LC.
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